

**Date: February 12, 2026**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited (NSE),</b> Exchange Plaza, C - 1, Block - G, Bandra - Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - 400 001.
<b>Symbol - LINCOLN</b>	<b>Scrip Code - 531633</b>

Dear Sir,

**SUB.: OUTCOME OF BOARD MEETING.**

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, February 12, 2026, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2025. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.

Meeting of the Board of Directors commenced at **10:10 A.M** and concluded at **11:15 A.M.**

Kindly take the same on your records.

Thanking you,

Yours faithfully,  
**For Lincoln Pharmaceuticals Limited**



*Trusha*  
LINCOLN PHARMACEUTICALS LTD.  
AHMEDABAD

**Trusha Shah**  
**Company Secretary &**  
**Compliance Officer**

Encl: A/a

# LINCOLN PHARMACEUTICALS LIMITED

**Regd. Office:** "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

**CIN:** L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,


**Website:** www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

**Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2025.**

Sr. No.	Particulars	(₹ in Lakhs Except Earnings Per Share Data)					
		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2025 (Un-Audited)	30/09/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/12/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/03/2025 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	16,632.20	16,336.39	14,655.17	48,375.26	45,504.70	62,323.01
	B) Other Income	1,514.55	723.21	897.00	3,764.93	2,935.68	2,247.71
	<b>Total Income (1)</b>	<b>18,146.75</b>	<b>17,059.60</b>	<b>15,552.17</b>	<b>52,140.19</b>	<b>48,440.38</b>	<b>64,570.72</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	4,768.00	5,719.90	5,015.90	16,584.83	16,000.79	21,393.84
	B) Purchase of Stock-In-Trade	2,502.53	2,172.27	1,860.91	6,257.86	5,379.48	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	325.44	(217.61)	(13.25)	(633.73)	(263.51)	884.00
	D) Employee Benefits Expenses	3,061.79	3,035.60	2,797.78	9,273.07	8,483.39	11,245.42
	E) Finance Costs	29.81	23.07	72.81	73.86	151.60	188.27
	F) Deprecation and Amortisation Expense	372.06	361.90	322.43	1,081.68	967.30	1,289.90
	G) Other Expenses	3,614.88	3,083.39	2,627.49	9,610.38	8,427.12	11,796.31
	<b>Total Expenses (2)</b>	<b>14,674.51</b>	<b>14,178.52</b>	<b>12,684.07</b>	<b>42,247.95</b>	<b>39,146.17</b>	<b>53,651.86</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
6	Tax Expense						
	A) Current Tax	601.00	861.90	754.90	1,875.20	1,818.00	2,487.20
	B) Deferred Tax	11.24	(12.45)	(13.34)	357.89	349.47	151.53
	C) Short / (Excess) Tax Provision	0.00	33.23	49.60	33.23	49.60	45.49
7	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
8	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	2.29	2.29	1.52	6.87	4.58	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
9	<b>Total Comprehensive Income</b>	<b>2,862.29</b>	<b>2,000.69</b>	<b>2,078.46</b>	<b>7,632.79</b>	<b>7,081.72</b>	<b>8,243.81</b>
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity						65,163.89
12	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
	(a) Basic (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11
	(b) Diluted (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11

**Notes:**

- 1 The above standalone un-audited financial results of the Company for the quarter and nine months ended on December 31, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 12, 2026. The auditor have carried out an limited review of the said financial results.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- 3 The Company has a single business segment namely 'Pharmaceutical Business'.
- 4 The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.



**For Lincoln Pharmaceuticals Limited**

*Mahendra G. Patel*

**Mahendra G. Patel**  
Managing Director  
DIN: 00104706

**Place: Ahmedabad**  
**Date: February 12, 2026**

# **SAMIR M. SHAH & ASSOCIATES**

## **Chartered Accountants**

"Heaven", 8, Western Park Society, Nr. Inductotherm,  
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

**Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To  
The Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended December 31, 2025 and for the year to date period from April 01, 2025 to December 31, 2025 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



(2)

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 12/02/2026



For, Samir M Shah & Associates  
Chartered Accountants,  
[Firm Regd. No. 122377W]

(Samir M Shah)

Partner

[M. No. 111052]

[UDIN: 26111052JQIUUVZ7353]

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com


Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2025.

Sr. No.	Particulars	₹ in Lakhs Except Earnings Per Share Data					
		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2025 (Un-Audited)	30/09/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/12/2025 (Un-Audited)	31/12/2024 (Un-Audited)	31/03/2025 (Audited)
1	<b>Income</b>						
	A) Revenue From Operations	16,632.20	16,336.39	14,655.17	48,375.26	45,504.70	62,323.01
	B) Other Income	1,514.55	723.21	897.00	3,764.93	2,935.68	2,247.71
	<b>Total Income (1)</b>	<b>18,146.75</b>	<b>17,059.60</b>	<b>15,552.17</b>	<b>52,140.19</b>	<b>48,440.38</b>	<b>64,570.72</b>
2	<b>Expenses</b>						
	A) Cost of Material Consumed	4,768.00	5,719.90	5,015.90	16,584.83	16,000.79	21,393.84
	B) Purchase of Stock-In-Trade	2,502.53	2,172.27	1,860.91	6,257.86	5,379.48	6,854.12
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	325.44	(217.61)	(13.25)	(633.73)	(263.51)	884.00
	D) Employee Benefits Expenses	3,061.79	3,035.60	2,797.78	9,273.07	8,483.39	11,245.42
	E) Finance Costs	29.81	23.07	72.81	73.86	151.60	188.28
	F) Deprecation and Amortisation Expense	372.06	361.90	322.43	1,081.68	967.30	1,289.90
	G) Other Expenses	3,614.88	3,083.39	2,627.49	9,610.38	8,427.12	11,796.30
	<b>Total Expenses (2)</b>	<b>14,674.51</b>	<b>14,178.52</b>	<b>12,684.07</b>	<b>42,247.95</b>	<b>39,146.17</b>	<b>53,651.86</b>
3	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>3,472.24</b>	<b>2,881.08</b>	<b>2,868.10</b>	<b>9,892.24</b>	<b>9,294.21</b>	<b>10,918.86</b>
6	Tax Expense						
	A) Current Tax	601.00	861.90	754.90	1,875.20	1,818.00	2,487.20
	B) Deferred Tax	11.24	(12.45)	(13.34)	357.89	349.47	151.53
	C) Short / (Excess) Tax Provision	Nil	33.23	49.60	33.23	49.60	45.49
7	<b>Net Profit / (Loss) For The Period (5-6)</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
8	Attributable to Non-Controlling Interest	Nil	Nil	Nil	Nil	Nil	Nil
	<b>Attributable to Owners of the Company</b>	<b>2,860.00</b>	<b>1,998.40</b>	<b>2,076.94</b>	<b>7,625.92</b>	<b>7,077.14</b>	<b>8,234.64</b>
9	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	2.29	2.29	1.52	6.87	4.58	9.17
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
10	<b>Total Comprehensive Income</b>	<b>2,862.29</b>	<b>2,000.69</b>	<b>2,078.46</b>	<b>7,632.79</b>	<b>7,081.72</b>	<b>8,243.81</b>
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
12	Other Equity						65,163.89
	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>						
13	(a) Basic (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11
	(b) Diluted (In ₹)	14.28	9.98	10.37	38.07	35.33	41.11

**Notes:**

- The above consolidated un-audited financial results of the Company for the quarter and nine months ended on December 31, 2025 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 12, 2026. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated un-audited financial results includes results of one subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel  
Managing Director  
DIN: 00104706

Place: Ahmedabad  
Date: February 12, 2026

# **SAMIR M. SHAH & ASSOCIATES**

## **Chartered Accountants**

"Heaven", 8, Western Park Society, Nr. Inductotherm,  
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

---

**Limited Review Report on consolidated unaudited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To  
The Board of Directors of,  
**Lincoln Pharmaceuticals Limited,**  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Lincoln Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2025 and for the year to date period from April 01, 2025 to December 31, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

- |                                    |   |                         |
|------------------------------------|---|-------------------------|
| A. Lincoln Pharmaceuticals Limited | - | Parent Company          |
| B. Zullinc Healthcare LLP          | - | Wholly-Owned Subsidiary |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflects total income of Rs.Nil Lakhs, total net loss of Rs.0.0004 Lakhs for the nine months ended December 31, 2025, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

For, Samir M Shah & Associates

Chartered Accountants,

[Firm Regd. No. 122377W]



(Samir M Shah)

Partner

[M. No. 111052]

[UDIN:26111052CONYVJ5309]

Place: Ahmedabad

Date: 12/02/2026

Media Release

## Lincoln Pharmaceuticals Ltd Net Profit rise 37.70% Y-o-Y to Rs. 28.60 crore in Q3 FY26, Revenue from Operation up 13.49% to Rs. 166.32 crore

- Revenue from operation in 9MFY26 at Rs. 483.75 crore, increase 6.31 % Y-o-Y
- EBITDA in 9MFY26 at Rs. 110.48 crore; EBITDA margin increase 6.10% Y-o-Y
- Net Profit in 9MFY26 at Rs. 76.26 crore; Net Profit margin rise 7.76 % Y-o-Y

### Highlights:-

- Company is targeting revenue of Rs 1,000 crore in next 3 years
- Crisil Ratings has reaffirmed its 'Crisil A/Stable/Crisil A1' ratings on the bank facilities of Lincoln Pharmaceuticals Ltd.
- FII holding in the company as on 31<sup>st</sup> December 2025 at 4.70%
- Aims to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments

### Financial Highlights (Consolidated)

(Amount in Cr except EPS)

Particulars	Q3 FY26	Q3 FY25	Y-O-Y (%)	9M FY26	9M FY25	Y-O-Y (%)
Revenue from Operation	166.32	146.55	13.49%	483.75	455.05	6.31%
EBITDA	38.74	32.63	18.73%	110.48	104.13	6.10%
Profit before Tax	34.72	28.68	21.06%	98.92	92.94	6.43%
Net Profit	28.60	20.77	37.70%	76.26	70.77	7.76%
E.P.S (Rs.)	14.28	10.37	37.70%	38.07	35.33	7.76%


**Ahmedabad (Gujarat), February 12, 2026:** Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN), one of India's leading healthcare companies has reported a consolidated net profit of Rs. 28.60 crore for the Q3 FY 2025-26 as compared to the net profit of Rs. 20.77 crore reported in Q3 FY 2024-25, increase of 37.70 % Y-o-Y. Revenue from Operation for the quarter ended December 2025 was reported at Rs. 166.32 crore as compared to the Rs. 146.55 crore in Q3 FY2024-25. EBITDA for Q3 FY26 was reported at Rs. 38.74 crore as compared to EBITDA of Rs. 32.63 crore in Q3 FY25 rise of 18.73 % Y-o-Y. EPS for Q3FY26 was reported at Rs. 14.28 per share.

CRISIL Ratings on 9<sup>th</sup> January has reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on Lincoln Pharmaceuticals' bank facilities, reflecting the promoters' strong industry experience, established market position, and healthy financial profile, despite working-capital intensity and regulatory and competitive challenges.

Company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) holding in the company as on 31<sup>st</sup> December 2025 was 4.70%.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India  
 Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288  
 E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.  
 Ta. : Kalol, Dist. Gandhinagar, (Guj.) | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



Speaking on the financial performance and future plans, **Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited**, said, “We are pleased to deliver another strong quarter, reflecting consistent execution and resilient demand across all business verticals. We are strengthening our R&D pipeline with over 100 new development programmes across multiple therapeutic segments and dosage forms, supported by bioequivalence studies and patent initiatives. These efforts reinforce our commitment to scientific innovation, unmet medical needs, and long-term, profitable growth. With a debt-free balance sheet, strong R&D capabilities, and a healthy product pipeline, we remain confident of sustaining 15–18% annual growth and achieving our Rs. 1,000 crore revenue target over the next three years.”

### **Highlights: - 9M FY26 Results**

For nine months ended December 2025, company reported consolidated net profit of Rs. 76.26 crore as against net profit of Rs. 70.77 crore reported in nine month ended December 2024, increase of 7.76 % Y-o-Y. Revenue from operation for 9MFY26 was reported at Rs. 483.75 crore as compared Rs. 455.05 crore in 9MFY25, growth of 6.31%. EBITDA for 9MFY26 was reported at Rs. 110.48 crore as compared to EBITDA of Rs. 104.13 crore in 9MFY25, rise of 6.10 % Y-o-Y. EPS for 9MFY26 was reported at Rs. 38.07 per share.

Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2–3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion.

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.



**Lincoln Pharmaceuticals Limited: <https://www.lincolnpharma.com/>**

**Providing Affordable and Innovative medicines for healthier lives.**

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has over 1,700 registered products and another 700 in pipeline. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with vision for nurturing innovations and bringing them to Indian patients at affordable cost to create **"Healthcare for All"**.

Lincoln Pharma has two state-of-the-art manufacturing facility units at Khatraj in Ahmedabad and Mehsana, Gujarat. Company's manufacturing facilities comply with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018, other ROW and emerging market regulatory approvals. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D facility of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600. Company has a wide national distribution network through 21+ Super Stockist in 26 states across India.

Going green, company has also set up a new Solar Plant at Mehsana factory and Khatraj factory in addition to at Radhanpur, Gujarat and two windmills. This way we are nearly a 100% green renewable energy consuming company resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

**For further information please contact:**

**Gopal Modi**  
DSNN Consultancy  
9099030184  
[gopal@dsnnconsultancy.com](mailto:gopal@dsnnconsultancy.com)



**Darshit A. Shah (CFO)**  
Lincoln Pharmaceuticals Ltd  
+91-79-4107-8048  
[darshit@lincolnpharma.com](mailto:darshit@lincolnpharma.com)